Drug Profile
TNB 383B
Alternative Names: ABBV-383; TNB-383BLatest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator TeneoBio; TeneoOne
- Developer AbbVie; TeneoOne
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 25 Jan 2024 AbbVie plans a phase I trial for Multiple myeloma (Second-line therapy or greater) in unknown location (SC, IV) (NCT06223516)
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting (ASH-2023)
- 09 Dec 2023 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)